Related Experiment Video
Updated: Dec 27, 2025

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Management of patients with heart failure treated in cardiology consultations: IC-BERG Study
V Barrios1, C Escobar2, C Ortiz Cortés3
1Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Madrid, España.
Insights
Clinical cardiologists agree that optimizing drug treatment for heart failure with reduced ejection fraction (HFrEF) is crucial, even in stable patients, to reduce mortality risk.
Area of Science:
- Cardiology
- Heart Failure Research
- Clinical Practice Guidelines
Background:
- Heart failure with reduced ejection fraction (HFrEF) poses significant mortality risks, often underestimated in stable patients.
- Current understanding of 'stable' HFrEF management requires refinement.
- Optimizing treatment for HFrEF is essential for patient outcomes.
Purpose of the Study:
- To assess clinical cardiologists' perception and management strategies for stable HFrEF.
- To establish a consensus on HFrEF definition, perception, and management.
- To develop recommendations for optimizing HFrEF care.
Main Methods:
- Modified Delphi method utilized with a panel of 150 experts.
- Questionnaire assessed definition, perception, and management of stable HFrEF.
- Consensus determined using a 9-point Likert scale.
Main Results:
- Consensus reached on 49 statements; disagreement on 16; 10 undetermined.
- High agreement (82%) on the definition of stable HF.
- Strong consensus (98.7%) that drug treatment optimization is necessary for stable HFrEF patients.
Conclusions:
- Understanding of stable HFrEF is currently insufficient.
- Treatment optimization is vital for apparently stable HFrEF patients.
- Proactive management is key to decreasing disease progression risk.
Objective:
To determine the perception and management of heart failure with reduced ejection fraction (HFrEF) by clinical cardiologists and to establish a consensus with recommendations.
Methods:
We employed the modified Delphi method among a panel of 150 experts who answered a questionnaire that included three blocks: definition and perception of patients with «stable» HFrEF (15 statements), management of patients with «stable» HFrEF (51 statements) and recommendations for optimising the management and follow-up (9 statements). The level of agreement was assessed with a Likert 9-point scale.
Results:
A consensus of agreement was reached on 49 statements, a consensus of disagreement was reached on 16, and 10 statements remained undetermined. There was consensus regarding the definition of «stable» HF (82%), that HFrEF had a silent nature that could increase the mortality risk for mildly symptomatic patients (96%) and that the drug treatment should be optimised, regardless of whether a patient with HFrEF remains stable in the same functional class (98.7%). In contrast, there was a consensus of disagreement regarding the notion that treatment with an angiotensin receptor-neprilysin inhibitor is justified only when the functional class worsens (90.7%).
Conclusions:
Our current understanding of «stable» HF is insufficient, and the treatment needs to be optimised, even for apparently stable patients, to decrease the risk of disease progression.
More Related Videos
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Related Concept Videos
Heart Failure VII: Nursing Interventions
Heart Failure V: Medical Management
Heart Failure IV: Classification and Diagnostic Evaluation
Cardiomyopathy V: Interprofessional Care
Heart Failure VI: Adjunct Therapies
Mitral Regurgitation IV: Nursing Management